drugset
drugset / Trial / NCT02175745

18F-FDOPA PET/CT or PET/MRI in Measuring Tumors in Patients With Newly-Diagnosed or Recurrent Gliomas

NCT02175745 ↗

Terminated 2 enrolled Erik Mittra National Cancer Institute (NCI) · collab
NaSingle-groupOpen-labelDiagnostic

Summary

To evaluate 18F-FDOPA PET obtained from PET/CT or PET/MRI imaging in patients with newly diagnosed or recurrent gliomas.

Timeline

Start
2014-12
Primary completion
2015-08
Completion
2015-12

Outcome

Outcome not reported

Stopped: “Re-evaluate indication with the referring physicians”

Drugs

EvaluationDrugModalityDoseRoute
Subject 18F-DOPA Diagnostic / imaging agent — Intravenous

Indications

adult anaplastic ependymoma adult brainstem glioma adult glioblastoma adult oligodendroglioma anaplastic astrocytoma anaplastic oligodendroglioma childhood brain stem glioma childhood cerebellar astrocytic neoplasm childhood cerebral astrocytoma childhood oligodendroglioma fibrillary astrocytoma gemistocytic astrocytoma giant cell glioblastoma gliomatosis cerebri gliosarcoma oligoastrocytoma optic pathway glioma pilomyxoid astrocytoma pineal gland astrocytoma protoplasmic astrocytoma subependymal giant cell astrocytoma